A. MENARINI INDUSTRIE FARMACEUTICHE RIUNITE SRL
Via Sette Santi, 1 50131 - Firenze (Firenze) Phone +39 055 56801 Fax +39 055 582771
Via Sette Santi, 1 50131 - Firenze (Firenze) Telefono +39 055 56801 Fax +39 055 582771
Everyday we put our values into action. 4 values, which have given life to Menarini and shaped its history.
Menarini is investing in advanced science and technology to develop a pipeline of new products that make a difference to the lives of patients affected by serious conditions.
MENARINI is a fully integrated privately owned pharma company with a long and successful heritage in strategic partnering across the globe. We have a profound know-how stemming from our strong R&D capabilities in key therapeutic areas, coupled with our excellence in commercial execution and our powerful direct presence on a global basis.
Our dedicated Corporate Business Development team is committed to assess and explore innovative new opportunities.
Donations of backpacks and cases for school, distribution of meals and medicines, promotion of sport, support for pregnant women and much more: being responsible for Menarini means transforming good intentions into concrete efforts. By helping others, we want to contribute to improve the world around us, starting with us.
What does it really make Menarini unique? The diversity and authenticity of our key resource - the People. Our cultural diversity helps us to drive innovation, adapt to business changes, face challenges, inspire ideas and develop our growth.
Menarini employees make all the difference, every day.
Ogni giorno mettiamo in pratica i nostri valori. 4 valori, che hanno dato vita a Menarini e ne hanno forgiato la storia.
Menarini investe continuamente nella scienza e nelle tecnologie all'avanguardia per lo sviluppo di una pipeline di nuovi prodotti che facciano la differenza nella vita dei pazienti affetti da gravi patologie.
Menarini è un’azienda privata completamente integrata con una lunga storia di collaborazioni di successo in tutto il Mondo. In Menarini abbiamo una conoscenza ed esperienza consolidata frutto della nostra capacità di Ricerca & Sviluppo nelle aree terapeutiche chiave, accompagnate da un’eccellente presenza capillare in tutto il Mondo.
Il nostro Team dedicato di Business Development è impegnato a valutare ed esplorare nuove opportunità innovative.
Dalla distribuzione di pasti e medicinali, dai kit per andare a scuola alla promozione dello sport all'aiuto per le donne in gravidanza: essere responsabili, per noi di Menarini, significa tradurre le buone intenzioni in sforzi concreti. Aiutando gli altri diamo il nostro contributo a migliorare il mondo che ci circonda, a partire da noi.
Che cosa rende davvero Menarini unica? La diversità ed autenticità del nostro valore più importante - le Persone. La nostra diversità culturale ci aiuta a guidare l'innovazione, ad adattarci ai cambiamenti di mercato, ad affrontare le sfide, ad ispirare idee e a promuovere la nostra crescita.
Chi lavora in Menarini fa la differenza, ogni giorno.
Chronic Myelomonocytic Leukemia (CMML) is a type of leukemia that is characterized by high numbers of white blood cells, called “monocytes”, in the blood and bone marrow. CMML is the most common of the MDS/MPN overlap diseases, with a prevalence estimated to be about 10% of that for MDS, and an annual incidence estimated to be 1.0 per 100,000 persons. The median age of occurrence of CMML is 70 years and a male predominance. Most patients present with non-specific features of ineffective hematopoiesis, particularly anemia and cytopenias, and clinical heterogeneity.
Myelofibrosis (MF) is a type of blood cancer in which the bone marrow is replaced by fibrous scar tissue. MF is a chronic myelproliferative neoplasm (MPN), defined as a group of clonal haematological malignancies that are characterized by excessive accumulation of one or more myeloid cell lineages and an inherent ability to transform to AML. The group includes polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF). The 2016 WHO diagnostic criteria for MPN includes the presence of JAK2, MPL and CALR driver mutation as a major requirement, in addition to BM morphology. ET is the most common subtype of MPN with an annual incidence rate ranging from 0.21 to 2.27 per 100,000 people, and prevalence rate between 11 and 43 per 100,000 people. The median age at diagnosis is around 60 years, with about 15–20% of patients <40 years, and a female pre- dominance. PV is the next most common subtype with an annual incidence of 0.84 per 100,000 per annum, a median age of about 60–70 years and a slight male predominance. PMF is the least frequent subtype, with an incidence of 0.22 to 1.5 per 100,000 per annum, a median age of about 65 years and no obvious sex predominance. Less than 5% of patients with PMF are under the age of 40 years at the time of diagnosis.
Menarini and Stemline teams are working relentlessly to develop new therapeutic options for these hematological diseases. We currently have two clinical development programs for AML and one program for MF and CMML.
Discover our stories from all over the world
Menarini � un�azienda privata completamente integrata con una lunga storia di collaborazioni di successo in tutto il Mondo. In Menarini abbiamo una conoscenza ed esperienza consolidata frutto della nostra capacità di Ricerca & Sviluppo nelle aree terapeutiche chiave, accompagnate da un�eccellente presenza capillare in tutto il Mondo.
Il nostro Team dedicato di Business Development � impegnato a valutare ed esplorare nuove opportunità innovative.
Scopri le nostre storie da tutto il mondo